Defining borderline resectability in pancreatic neuroendocrine tumors and the role of neoadjuvant therapy.

Authors

Wilson M Alobuia, Susan Tsai, Mary Dillhoff, Timothy M Pawlik, Alex B Blair, Vineeth Sukrithan, Bhavana Konda, Jordan M Cloyd

Published in

HPB : the official journal of the International Hepato Pancreato Biliary Association. Sep 10, 2026. Epub Sep 10, 2026.

Abstract

Although surgical resection offers the best outcomes for patients with localized/oligometastatic pancreatic neuroendocrine tumors (pNET), definitions for borderline resectable (BR) disease to guide patient selection and neoadjuvant therapy (NT) have not been established. This study sought to validate a proposed definition of BR-pNET and evaluate the impact of NT and surgical resection on overall survival (OS).
Using the National Cancer Database, patients with invasive, well-differentiated pNETs were classified as BR [T4 stage and/or liver-only metastases] or resectable (Among 15,473 patients, BR-pNET [2,945 (19%)], was independently associated with worse OS (HR 3.24, 95% CI 2.95-3.55; p<0.001). Among BR-pNET patients, resection was associated with longer median OS (128.6 vs 46.4 months; p<0.001). This benefit persisted in a 6-month landmark analysis (HR 0.36, 95% CI 0.30-0.44). NT use was uncommon (1.8%) and was not independently associated with survival (HR 1.14, 95% CI 0.66-1.97; p = 0.625).
Among patients with well-differentiated pNET, borderline resectability was associated with worse OS, although surgical resection conferred meaningful survival benefit. The use of NT was uncommon and not associated with improved OS in this retrospective cohort.

PMID:
42823259
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.